comparemela.com

Latest Breaking News On - Molecular therapeutics - Page 15 : comparemela.com

Research Analysts Price Target Changes for April 1st (AAPL, ABCB, ABNB, AFMD, ALL, ALT, AMX, AMZN, ANAB, ANNX)

Research Analysts’ price target changes for Monday, April 1st: Apple (NASDAQ:AAPL) had its target price lowered by Loop Capital from $185.00 to $170.00. Loop Capital currently has a hold rating on the stock. Ameris Bancorp (NASDAQ:ABCB) had its target price lowered by Truist Financial Co. from $60.00 to $54.00. The firm currently has a buy […]

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024

NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in.

4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease Why Is 4D Molecular Therapeutics Stock Falling on Thursday? - 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and Phase 3 clinical trial preparations.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.